Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone86-21-6163-2588
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
Employees309
Next Earnings DateN/A
OptionableOptionable
Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions
What is Zai Lab's stock symbol?
Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
What price target have analysts set for ZLAB?
7 Wall Street analysts have issued 1 year price targets for Zai Lab's stock. Their predictions range from $34.70 to $65.00. On average, they expect Zai Lab's share price to reach $45.45 in the next year. This suggests a possible upside of 48.9% from the stock's current price. View Analyst Price Targets for Zai Lab.
What is the consensus analysts' recommendation for Zai Lab?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.
Has Zai Lab been receiving favorable news coverage?
News headlines about ZLAB stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Zai Lab earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Zai Lab.
Who are some of Zai Lab's key competitors?
Some companies that are related to Zai Lab include Perrigo (PRGO), SAGE Therapeutics (SAGE), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Beigene (BGNE), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Reata Pharmaceuticals (RETA), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC) and GW Pharmaceuticals PLC- (GWPH).
What other stocks do shareholders of Zai Lab own?
Who are Zai Lab's key executives?
Zai Lab's management team includes the folowing people:
- Dr. Ying Du, Founder, Chairman & CEO (Age 53)
- Mr. Tao Fu, Pres, COO & Director (Age 47)
- Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
- Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)
- Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)
When did Zai Lab IPO?
(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.
How do I buy shares of Zai Lab?
Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zai Lab's stock price today?
One share of ZLAB stock can currently be purchased for approximately $30.53.
How big of a company is Zai Lab?
Zai Lab has a market capitalization of $1.77 billion and generates $130,000.00 in revenue each year. The company earns $-139,070,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Zai Lab employs 309 workers across the globe.View Additional Information About Zai Lab.
What is Zai Lab's official website?
How can I contact Zai Lab?
Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]
MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
